Radiprodil - GRIN Therapeutics
Latest Information Update: 17 Sep 2024
At a glance
- Originator GRIN Therapeutics
- Class Antiepileptic drugs; Behavioural disorder therapies; Non-opioid analgesics; Small molecules
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Focal cortical dysplasia; Tuberous sclerosis
- Phase I Behavioural disorders; Seizures
Most Recent Events
- 09 Sep 2024 Efficacy and adverse events data from a phase Ib trial in Behavioural disorders and Seizures released by GRIN Therapeutics
- 09 Sep 2024 GRIN Therapeutics plans a pivotal phase III trial
- 10 Jul 2024 Phase-I/II clinical trials in Focal cortical dysplasia (In adolescents, In children, In infants) in Spain, Netherlands, Poland, Italy (PO) (NCT06392009) (EUCT2023-506301-20-00)